Alpelisib and Primidone interaction

Alpelisib and Primidone: the Alpelisib prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Alpelisib (VIJOICE) label · effective 2025-11-04

Major

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer.

Drug interactionsby drug classView label on DailyMed
Major

Effect of Other Drugs on VIJOICE CYP3A4 Inducers Avoid coadministration of VIJOICE with strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4.

Drug interactionsby drug classView label on DailyMed
Moderate

Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4.

Drug interactionsby drug classView label on DailyMed
Moderate

Concomitant use of VIJOICE with a strong CYP3A4 inducer may decrease alpelisib concentration [see Clinical Pharmacology (12.3)] , which may decrease alpelisib activity.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.